Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma
Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma
复制标题
DOI：
10.1111/hepr.12041
复制
发表时间：
2013-09-01
影响因子：
4.2
通讯作者：
Kumada, Hiromitsu
中科院分区：
文献类型：
--
作者：
Seko, Yuya;Ikeda, Kenji;Kumada, Hiromitsu
目的：不能切除的肝细胞癌（HCC）患者常接受经导管动脉化疗栓塞（TACE）。米铂是一种亲脂性顺铂衍生物，用于TACE，对HCC有效。然而，温热与室温miriplatin之间的抗肿瘤疗效的差异是uncleared.Methods：化疗疗效评价动态CT TACE后1-3个月，根据修改的实体瘤疗效评价标准。共203例首次接受TACE联合Miriplatin治疗的HCC患者被纳入随访研究，以回顾性研究其疗效和安全性。总体而言，45例患者接受TACE与温热（40摄氏度）miriplatin和158例患者接受TACE与室温miriplatin.Results：70例（44.3%）与室温miriplatin治疗和32例（71.1%）谁收到温热miriplatin经历了完全或部分反应。多变量分析确定了米铂温度（温热的米铂，风险比（RR）=2.26，P=0.047），肿瘤数量（孤立，RR=3.48，P=0.007），甲胎蛋白（AFP）水平（
Aim: Patients with unresectable hepatocellular carcinoma (HCC) often undergo transcatheter arterial chemoembolization (TACE). Miriplatin is a lipophilic cisplatin derivative used in TACE that is effective in HCC. However, the difference in antitumor efficacy between warmed versus room temperature miriplatin is unclear.Methods: Chemotherapy efficacy was evaluated by dynamic computed tomography 1-3 months after TACE, according to the Modified Response Evaluation Criteria in Solid Tumors. A total of 203 patients with HCC who received TACE with miriplatin for the first time were included in a follow-up study to retrospectively investigate its efficacy and safety. Overall, 45 patients underwent TACE with warmed (40 degrees C) miriplatin and 158 patients received TACE with room temperature miriplatin.Results: Seventy patients (44.3%) treated with room temperature miriplatin and 32 patients (71.1%) who received warmed miriplatin experienced complete or partial responses. Multivariate analysis identified miriplatin temperature (warmed miriplatin, risk ratio (RR)=2.26, P=0.047), tumor number (solitary, RR=3.48, P=0.007), -fetoprotein (AFP) level (